Efficacy and safety studies review of Teraligen usage in psychiatric practice and general medicine

Shmilovich A.A.; Goncharenko S.N.

doi:https://doi.org/10.17116/jnevro202212206155

Close metadata

OBJECTIVE

Determination of the dose-dependent effect of the Teraligen for various nosological forms of disorders in psychiatric practice and general medicine.

MATERIAL AND METHODS

Analysis of 98 publications included in the database of the RISC (2012—2021) with the identification of disorders (according to ICD-10) in which Teraligen is prescribed or can be used (in adults and children from the age of 7).

RESULTS

Despite a rather long and successful history use, research work on the study drug Teraligen continues. Currently Teraligen is widely and actively used by doctors of various specialties in the psychiatry, neurology, pediatrics, gerontology, internal medicine, gastroenterology, gynecology, cardiology, endocrinology and other disciplines. The drug is presented in several release forms: Teraligen 5 mg tablets; Teraligen retard 20 mg; Teraligen solution for intravenous injections. Teraligen is characterized by the following psychotropic effects: anxiolytic (++ — a distinct, moderately pronounced effect); sedative (++); hypnotic (++); antidepressant (+ — the effect is distinct, but expressed slightly and does not determine the drug main prescriptions spectrum); antipsychotic (± — the effect is weakly expressed and clinically insignificant when using conventional (5—80 mg/day) drug dosages).

CONCLUSION

According to the authors, the main effect of the «small» neuroleptic/antipsychotic Alimemazine (Teraligen ) is primarily aimed at pathological anxiety and affective instability. Its use is possible in various age groups, as it has a fairly high safety. In addition, like other «small» neuroleptics/antipsychotics with a predominantly sedative effect, the drug can be used to correct neuroleptics-prolongs side effects with dominant manifestations in the form of anxiety, irritability and insomnia.

Keywords:

Teraligen

anxiety disorders

anxiety-depressive disorders

phobic disorders

somatoform disorders

neurotic disorders

stress-related disorders

sleep disorders

Authors:

Shmilovich A.A.

Pirogov Russian National Research Medical University

Goncharenko S.N.

Pirogov Russian National Research Medical University

Received:

11.03.2022

Accepted:

30.03.2022

Close metadata

References:

Asadullin AR, Yuldashev VL, Asadullina GM, et al. Efficacy and safety of the use of the drug Alimemazine (Teralidzhen) for the relief of anxiety in patients with alcohol dependence syndrome. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(1-2):39-44. (In Russ.). https://doi.org/10.17116/jnevro20181181239-44
Becker RA, Bykov YuV. Alimemazine: a review of application. Psychiatry and Psychopharmacotherapy. 2016;18(6):10-20. (In Russ.).
Ibragimov DF. Alimemazine in medical practice. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2008;108(9):76-78. (In Russ.).
Ikhsanova DT. The use of Teraligen in psychovegetative syndrome as part of an endogenous mental disorder. In the collection: Natural sciences and medicine: theory and practice. Collection of articles based on materials of the XXXIII International Scientific and Practical Conference. Novosibirsk. 2021;42-48. (In Russ.).
Silverstova YuV, Kuznechenkova LV, Gavrilina OV. Experience with the use of the injectable form of the drug Alimemazine (Teralijen) in patients with mental and behavioral disorders. In the collection: National projects — a priority for the development of healthcare in the regions. Materials of the 54th interregional scientific and practical medical conference. 2019;484-485. (In Russ.).
Morozova MA, Alekseev AA, Rupchev GE. Alimemazine: a convenient therapeutic tool for solving some complex problems in the treatment of functional psychotic disorders (clinical cases). Modern Therapy of Mental Disorders. 2017;2:40-43. (In Russ.).
Savelyev DV, Reznik AM, Chernov AS, et al. The use of Alimemazine in the treatment of excitation in patients with schizophrenia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(6-2):68-76. (In Russ.). https://doi.org/10.17116/jnevro202012006268
Demyanov IA, Boyko EO, Zaitseva OG, Pogodina MG. Evaluation of the effectiveness of the drug Alimemazine (solution for intramuscular injection) in the treatment of anxiety and depressive disorders. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(8):32-37. (In Russ.). https://doi.org/10.17116/jnevro201911908132
Edin AS. To the question of the use of alimemazine (teraligen) in patients with atopic dermatitis in combination with anxiety and depressive disorder. Consilium Medicum. 2018;20(2):145-150. (In Russ.).
Medvedev VE. Alimemazine in psychiatry and psychosomatics. Psychiatry and Psychopharmacotherapy. 2018;20(3-4):26-33. (In Russ.).
Etingof AM. Efficacy and safety of Teraligen in everyday practice. Farmateka. 2014;19(292):8-13. (In Russ.).
Yakhno NN, Parfenov VA, Reikhart DV, et al. Multicenter non-interventional prospective observational program to study the practice of prescribing Teraligen in patients with a diagnosis of vegetative disorder (Start-2: Russian experience with the Russian-language validated version of the 4DSQ questionnaire. Interim analysis). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(5):27-33. (In Russ.). https://doi.org/10.17116/jnevro20151155127-33
Barantsevich ER, Golovkova MS, Dzhulai IA, et al. Efficacy and safety of Teraligen in patients with stage I and II dyscirculatory encephalopathy and psychovegetative syndrome. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(12):86-91. (In Russ.). https://doi.org/10.17116/jnevro201511511286-91
Ivashkin VT, Okhlobystina OZ, Maevskaya MV, et al. Dynamics of somatic and comorbid mental disorders (distress, anxiety, somatization and depression) in patients with irritable bowel syndrome on Alimemazine therapy: results of a non-interventional observational program («Terra»). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(6):38-50. (In Russ.). https://doi.org/10.22416/1382-4376-2018-28-6-38-50
Lyubimov AV, Karchaa AR. The use of Teraligen in the treatment of suprasegmental (cerebral) vegetative disorders. Scientific Bulletin of the Belgorod State University. Series: Medicine. Pharmacy; 2012;4(123):20-25. (In Russ.).
Raginene IG, Akhapkin FA. Somnological and vegetative disorders in neurological patients with acute vascular pathology. Effective Pharmacotherapy. 2014;49:4-7. (In Russ.).
Aleshina NV. The use of the drug «Teralidzhen» in the structure of pharmacotherapy of early childhood autism (procedural and organic). Psychiatric Health. 2014;12(2-93):70-72. (In Russ.).
Aleshina NV. Therapy of autistic disorders with Teraligen (Alimemazine) in pediatric practice on an outpatient basis. Psychiatry and Psychopharmacotherapy. 2018;20(1):23-26. (In Russ.).
Aleshina NV, Filippova NV, Barylnik YuB. Teraligen in the complex therapy of organic and procedural early childhood autism. International Research Journal. 2014;2-3(21):89-90. (In Russ.).
Zueva GA. Experience in the use of alimemazine tartrate for the correction of sleep disorders in adolescents with tension-type headache. In the collection: Topical issues of rehabilitation in neurology and psychiatry. Materials of the scientific-practical conference. Tver State Medical Academy of the Ministry of Health of Russia. 2014;16-18. (In Russ.).
Mazaeva NA, Golovina AG. Alimemazine in outpatient therapy of non-psychotic mental disorders in adolescents. Psychiatry. 2015;1(65):11-16. (In Russ.).
Malinina EV, Chizhova TN, Zabozlaeva IV, Pirogova AV. A study of the efficacy and tolerability of Alimemazine in children with mixed emotion and behavior disorder. Doctor.Ru. 2015;5-6(106-107):67-70. (In Russ.).
Akarachkova ES. On the issue of diagnosis and treatment of psycho-vegetative disorders in general somatic practice. Attending Doctor. 2010;10:5-8. (In Russ.).
Kovaleva AA, Maloletkina TS. Chemical-toxicological analysis of Alimemazine (Teralidgen). In the collection: Actual problems of pharmacology and pharmacy. Annual collection of scientific and methodical works of teachers, young scientists and students of the Faculty of Pharmacy. Barnaul. 2014;57-61. (In Russ.).
Reikhart DV, Arnautov VS, Globenko AA, et al. Bioavailability and pharmacokinetic parameters of Teraligen Retard and Teraligen Valenta tablets at a single dose in healthy volunteers. Chemical Pharmaceutical Journal. 2017;51(8):25-30. (In Russ.). https://doi.org/10.1007/s11094-017-1675-3
Rybasova AS, Remezova IP, Lazaryan DS, Maksimenko TI. Isolation, detection and quantification of Alimemazine in model mixtures of urine, saliva and blood plasma. Bulletin of the Volgograd State Medical University. 2017;1(61):59-61. (In Russ.). https://doi.org/10.19163/1994-9480-2017-1(61)-59-61
Pushkarev DF. Alimemazine in psychiatric practice and general medicine (literature review). Mental Disorders in General Medicine. 2013;1:56-61. (In Russ.).
Katzman M.A., Bleau P., Blier P., et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):1. https://www.biomedcentral.com/1471-244X/14/S1/S1
Swinson R, Antony M, Bleau P, et al. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry. 2006;51:9-91.
Stein MB, Goin MK, Pollack MH, et al. Practice Guideline for the Treatment of Patients With Panic Disorder. Second Edition. American Psychiatric Association. APA. 2009, Copyright 2010.
Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439. https://doi.org/10.1177/0269881114525674
Bandelow B, Werner AM, Kopp I, et al. The German Guidelines for the treatment of anxiety disorders: first revision. Eur Arch Psychiatry Clin Neurosci. 2021;1-12. https://doi.org/10.1007/s00406-021-01324-1
Locke AB, Kirst N, Shultz CG. Diagnosis and Management of Generalized Anxiety Disorder and Panic Disorder in Adults. Am Fam Physician. 2015;91(9):617-624.
Gautam S, Jain A, Gautam M, et al. Clinical Practice Guidelines for the Management of Generalised Anxiety Disorder (GAD) and Panic Disorder (PD). Indian J Psychiatry. 2017;59(suppl 1):67-73. https://doi.org/10.4103/0019-5545.196975
Clinical guidelines: Anxiety-phobic disorders (F40). Adults. Developer of clinical guidelines Russian Society of Psychiatrists. Approved by the Ministry of Health of the Russian Federation, 2021. (In Russ.).
Clinical guidelines: Generalized anxiety disorder (F41.1). Adults. Developer of clinical guidelines Russian Society of Psychiatrists. Approved by the Ministry of Health of the Russian Federation, 2021. (In Russ.).
Clinical recommendations: Panic disorder (F41.0). Adults. Developer of clinical guidelines Russian Society of Psychiatrists. Approved by the Ministry of Health of the Russian Federation, 2021. (In Russ.).
Clinical guidelines: Obsessive-compulsive disorder (F42). Adults. Developer of clinical guidelines Russian Society of Psychiatrists. Approved by the Ministry of Health of the Russian Federation, 2021. (In Russ.).